Resources

Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia

• External Link

Results of a Phase I Dose Escalation Study of the Novel, Oral CRM1 Selective Inhibitor of Nuclear Export (SINE) KPT-335 in Dogs with Spontaneous Non-Hodgkin’s Lymphomas (NHL)

•  ()

Potent anticancer activity against both BRAF-mutant and BRAF wild-type melanoma cell lines using a novel CRM1 nuclear export inhibitor

• PDF (1.40 MB)

KPT-0127 Induces Selective Apoptosis of Malignant Cells by CRM1 Inhibition and Elevation of Regulatory Proteins p53, p21, FOXO and IkB

• PDF (1.24 MB)

KPT-0127, a Novel, Potent and Selective Inhibitor of CRM1-Mediated Nuclear Export Shows Selective Cytotoxicity for the Treatment of Hematological Cancers

• PDF (1.17 MB)